Life Science

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.

Inhibitor of NF-&kappaB activation that blocks the phosphorylation of IKK and I&kappaB (IC50 ~ 40 &muM) dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.

Inhibitor of NF-&kappaB activation that blocks the phosphorylation of IKK and I&kappaB (IC50 ~ 40 &muM) dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.

Inhibitor of NF-&kappaB activation that blocks the phosphorylation of IKK and I&kappaB (IC50 ~ 40 &muM) dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.

Inhibitor of NF-&kappaB activation that blocks the phosphorylation of IKK and I&kappaB (IC50 ~ 40 &muM) dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.

A minor component of avermectin broth, used broadly against nematodes, ticks, flies, and ants.

A minor component of avermectin broth, used broadly against nematodes, ticks, flies, and ants.